Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement

This article was originally published in RPM Report

Executive Summary

States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.

You may also be interested in...



AstraZeneca Hit With New Compliance Mandates In Seroquel Settlement With States

A $68.5 million settlement agreement with the states imposes restrictions on physician detailing and the presentation of clinical trial data, among other things.

AstraZeneca Hit With New Compliance Mandates In Seroquel Settlement With States

A $68.5 million settlement agreement with the states imposes restrictions on physician detailing and the presentation of clinical trial data, among other things.

Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel